摘要
本研究探讨骨髓瘤患者骨髓细胞中pdcd5基因的表达。应用ELISA方法和实时定量逆转录-聚合酶链反应(real-time quantitative RT-PCR,RQ-RT-PCR)技术,检测多发性骨髓瘤(MM)患者及正常人PDCD5蛋白和基因的表达,比较pdcd5基因的表达与患者临床特征的关系。结果表明:45例初治及难治复发MM患者血浆PDCD5蛋白水平显著低于20例健康人和20例治疗有效患者,分别为(16.91±0.28)ng/ml,(19.11±0.29)ng/ml,(17.94±0.154)ng/ml(p均<0.05)。45例初治及难治复发MM患者骨髓细胞pdcd5基因表达量显著低于正常人,分别为0.64±0.47和1.28±1.21,p<0.05。结论:多发性骨髓瘤患者低表达PDCD5,pdcd5基因可能参与了MM的发病机制。
The aim of this study was to investigate the gene expression of programmed cell death 5 （ pdcd5 ） in plasma and bone marrow cells from patients with multiple myeloma （MM）. Enzyme liked immunosorbent assay （ELISA） and real-time quantitative reverse transcrpfion polymerase chain reaction （RQ-RT-PCR） were used to examine pdcd5 gene expression in plasma and marrow cells in 45 MM patients and 20 normal controls. The results showed that serum levels of PDCD5 protein in 45 MM patients were lower significantly compared with the normal controls and 20 responsive patients after chemotherapy, their plasma levels were （ 16.91 ± 0.28 ） ng/ml, （ 19. 11 ± 0.29 ） ng/ml and （ 17.94 ± 0. 154） ng/ml respectively （p 〈 0.05 ）. The pdcd5 gene expression levels detected by RQ-RT-PCR in 45 MM patients were lower significantly compared with the normal controls ,their pdcd5 gene expression levels were 0.64 ± 0.47 and 1. 28 ± 1.21 respectively （p 〈 0.05 ）. It is concluded that the PDCD5 protein expression levels are low in patients with MM. These findings suggest that abnormal expression of pdcd5 may be involved in the pathogenesis of MM.
出处
《中国实验血液学杂志》
CAS
CSCD
2010年第3期634-637,共4页
Journal of Experimental Hematology
基金
国家自然科学基金(编号30670894)
北京大学人民医院研究与发展基金(编号RDB2009-40)
关键词
pdcd5基因
多发性骨髓瘤
骨髓细胞
programmed cell death 5 gene
multiple myeloma
bone marrow cell
